THYNTRA
LIVE

Serial Number

99512467

Owner

Cogthera, LLC

Attorney

Jessica R. Manganello

First Use Date

Sep 1, 2025

Filing Date

Nov 24, 2025

Add to watchlist:

No watchlists yet
View on USPTO

THYNTRA Trademark

Serial Number: 99512467

THYNTRA is a trademark filed by Cogthera, LLC on November 24, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Cogthera, LLC (2 trademarks)

20500 Riggs Hill Way
Brookeville, MD 20833

Entity Type: 16

Trademark Details

Filing Date

November 24, 2025

Registration Date

Not Registered

First Use Anywhere

September 1, 2025

First Use in Commerce

November 11, 2025

Goods & Services

Pharmaceutical preparations for the treatment and prevention of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Pharmaceutical preparations for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Biological preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Biological preparations for the prevention and treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Biologics in the nature of pharmaceutical preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; In vitro diagnostic preparations for medical use; Antibody reagents used for the detection of antigens in cells and tissue for medical purposes; Medical diagnostic reagents; Diagnostic reagents for medical use; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Reagents for use in diagnostic tests for medical purposes; Diagnostic reagents for medical purposes for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Pharmaceutical preparations for gene therapy for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Drug delivery agents in the form of intranasal spray (nasal sprays), inhalation (aerosols and dry powers), oral (tables, capsules, liquids), topical (creams, gels, transdermal patches), intravenous, and intrathecal routes that facilitate the delivery of pharmaceutical preparations; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases.; Clinical medical reagents; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes

Filing History

APPLICATION FILING RECEIPT MAILED
Nov 24, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 24, 2025 NWOS
NEW APPLICATION ENTERED
Nov 24, 2025 NWAP